What are the pros and cons of outpatient intravenous ketamine (ketamine) treatment for depression, including its effects on memory, ability to work after infusion, mechanism of action, recommended number of infusions, frequency, and duration for a nurse practitioner?

Outpatient IV Ketamine for Depression: Comprehensive Clinical Guide

Ketamine is now recommended as a treatment option for patients with treatment-resistant depression (TRD) who have failed at least 2 adequate antidepressant trials, representing a significant shift from the 2016 guideline that recommended against its use outside research settings. 1

Indications and Patient Selection

Reserve ketamine for patients who have not responded to several adequate pharmacologic trials—not as first-line treatment. 1

• Appropriate candidates: Adults with Major Depressive Disorder or Bipolar Disorder with minimum Stage 2 antidepressant resistance (≥2 failed adequate trials) 2
• Also supported for short-term reduction in suicidal ideation in patients with MDD 1
• The 2022 VA/DoD Clinical Practice Guideline marks this as a major change from prior recommendations 1

Efficacy: What to Expect

Depression Outcomes

Ketamine produces rapid antidepressant effects within 24 hours, with improvements persisting 3-7 days after a single infusion. 1, 3

• Single infusion effects:

  • Significant improvement at 4 hours (effect size -1.74) 3
  • Sustained improvement at 24 hours (effect size -1.15) 3
  • Benefits persist through 3 days and 1 week 1, 3
  • When added to ongoing antidepressants: improvements last up to 7 days 1
  • As monotherapy: no significant difference at 7 days 1

• Repeated infusion outcomes (after 4-6 weeks):

  • Response rate (≥50% improvement): 26-27% 2, 4
  • Remission rate: 13-15% 2, 4
  • Mean 47.2% reduction in depression symptoms 5
  • Improvements sustained over 6 months with maintenance dosing 4

Suicidal Ideation

Ketamine rapidly reduces suicidal ideation, with large effect sizes at 24 hours (effect size -0.69) and sustained reduction at 1 month (effect size -0.70). 3

• Repeated infusions show similar reduction (effect size -0.72) 3
• Largest effects in patients with high baseline suicidal ideation (effect size 2.36 at 40 minutes) 6

Additional Benefits

• Anxiolytic effects (significant reduction in GAD-7 scores) 2
• Improved psychosocial function (Sheehan Disability Scale) 2
• Pain reduction in cancer patients 7

Dosing Protocol

Standard Induction Dose

The standard dose is 0.5 mg/kg IV infused over 40 minutes. 6, 8

• Dose range: 0.1-0.75 mg/kg depending on response 8
  • Some patients respond to as low as 0.1 mg/kg 8
  • Others may require up to 0.75 mg/kg 8
• Infusion duration: Safety and efficacy demonstrated across 2-100 minutes, though 40 minutes is conventional 8

Critical Safety Requirements (FDA Label)

Ketamine must be administered by or under the direction of physicians experienced in general anesthesia, airway management, and ventilation. 9

• Continuous vital sign monitoring required 9
• Emergency airway equipment must be immediately available 9
• Do NOT administer 100 mg/mL concentration IV without proper dilution 9
• Administer slowly over 60 seconds minimum to avoid respiratory depression 9

Treatment Course and Frequency

Induction Phase (First 6 Weeks)

Begin with twice-weekly infusions, transitioning to weekly or less frequent dosing based on response. 1, 4

• Initial frequency: Every 5 days 4
• Typical induction: 8-10 infusions over 6 weeks 5, 4
• Assess response at 6 weeks 4

Maintenance Phase

Taper frequency to every 3-4 weeks once response achieved, dosing just before the previous session's effect wears off. 8, 4

• Frequency decreases from every 5 days to every 3-4 weeks over first 5 months 4
• Mean of 18 total infusions over 12 months in VA data 4
• Individualize frequency: Dose a little before the effect of the previous session is expected to wear off 8

Cognitive Effects and Memory

Short-Term Effects

Ketamine does not impair cognition and may actually enhance specific cognitive functions, particularly processing speed, working memory, and executive control. 10, 5

• Procognitive effects observed in:

  • Processing speed (frequently improved) 10
  • Working memory (frequently improved) 10
  • Executive control, especially inhibitory performance on Stroop tasks 10
  • Attention (preserved or modestly improved) 10

• Heterogeneous results in:

  • Verbal and visual memory 10

Long-Term Cognitive Safety

Repeated ketamine infusions (8-10 sessions) do not impair cognitive performance as measured by Montreal Cognitive Assessment (MoCA). 5

• No evidence of cognitive deterioration reported across studies 10
• Baseline cognition may positively predict antidepressant response (Pearson correlation 0.453) 5

Ability to Work After Treatment

Patients require monitoring for 2 hours post-infusion and should not drive or operate machinery immediately after treatment. 1

• Dissociation severity significantly reduces with subsequent infusions compared to baseline 2
• Acute dissociative effects are transient and resolve during treatment 2, 3
• Plan for transportation home after each session
• Most patients can return to normal activities the following day, though this should be individualized

Mechanism of Action

Ketamine acts as a non-selective, non-competitive antagonist of the NMDA receptor, an ionotropic glutamate receptor. 9, 11

• Downstream modulation of glutamatergic signaling 11
• Enhancement of synaptic plasticity and neural connectivity 11
• The major metabolite norketamine demonstrates activity at the same receptor with approximately 1/3 the potency 9
• Procognitive effects, particularly in executive control, may mediate ketamine's antisuicidal action 10

Safety Profile and Adverse Events

Common Transient Side Effects

• Dissociation (decreases with repeated infusions) 2
• Headache 3
• Fatigue 7
• Dizziness 7
• Nystagmus with pupillary dilation 9
• Salivation and lacrimation 9

Cardiovascular Effects

Ketamine increases blood pressure, heart rate, and cardiac output through indirect sympathomimetic activity. 9

• Blood pressure peaks 10-50% above baseline within minutes 9
• Usually returns to baseline within 15 minutes 9

Serious Adverse Events

Reported serious adverse events (hospitalizations, deaths) were unrelated to ketamine interventions in clinical trials. 3

Critical Warning: Genitourinary Effects

In individuals with chronic ketamine use for off-label indications, case reports exist of genitourinary pain potentially related to treatment. 9

• Consider cessation if genitourinary pain continues with other genitourinary symptoms 9

Long-Term Safety Concerns

Ketamine lacks long-term efficacy and safety trials in MDD—this is the primary limitation. 1

• Bulk of evidence is short-term (7-day efficacy) 1
• Risk of abuse must be considered, especially for domiciliary treatment 8

Practical Implementation for Nurse Practitioners

Pre-Treatment Requirements

1. Patient screening:

   • Confirm ≥2 failed adequate antidepressant trials
   • Assess cardiovascular status (ketamine increases BP/HR)
   • Screen for substance use history
   • Ensure nil per os (NPO) status 9

2. Administer antisialagogue prior to induction to manage salivation 9

3. Consider benzodiazepine co-administration for prevention of neuropsychological manifestations during emergence 9

During Infusion

• Continuous vital sign monitoring 9
• Emergency airway equipment immediately available 9
• Monitor for dissociative symptoms
• Infuse slowly over minimum 40 minutes 8

Post-Infusion

• Mandatory 2-hour monitoring period (similar to esketamine REMS requirements) 1
• Assess for adverse effects
• Ensure safe transportation home
• Document response using standardized scales (PHQ-9, QIDS-SR16)

Comparison with Esketamine

Unlike ketamine, esketamine (intranasal) has FDA approval and REMS requirements including pharmacy certification, healthcare setting certification, and mandatory 2-hour post-treatment monitoring. 1

• Esketamine has evidence for longer-term maintenance use 1
• Twice-weekly esketamine dosing improved symptoms at 28 days 1
• Both are reserved for patients with failed prior therapies 1

Key Limitations and Caveats

1. Only a minority of patients achieve response or remission (26-27% response, 13-15% remission) 2, 4

2. Long-term outcomes poorly established 1, 11

3. Study heterogeneity: Variable dosing protocols, short follow-up periods, and inconsistent outcome measures 11

4. No definitive guidance on optimal maintenance strategies 8, 4

5. Access challenges: Requires frequent onsite visits, specialized monitoring, and experienced providers 1

Clinical Bottom Line

Ketamine represents a rapid-acting treatment option for TRD with unique benefits in suicidal ideation and cognitive function, but should be reserved for patients who have failed multiple antidepressant trials. The standard protocol involves 0.5 mg/kg IV over 40 minutes, starting with twice-weekly infusions for 6 weeks, then tapering to maintenance dosing every 3-4 weeks based on individual response. While cognitive effects are favorable and acute side effects are transient, the lack of long-term safety data and modest response rates (approximately 25-30%) necessitate careful patient selection and ongoing monitoring. Patients require 2-hour post-infusion observation and should not drive immediately after treatment, but most can resume normal activities the following day.